BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ADBRY (tralokinumab-ldrm) by Leo Pharma is interleukin-13 antagonists [moa]. First approved in 2021.
Drug data last refreshed 23h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADBRY (tralokinumab-ldrm) is a monoclonal antibody that antagonizes interleukin-13, a key driver of type 2 inflammation. It is administered by injection and is indicated for atopic dermatitis and other IL-13–mediated inflammatory conditions. The drug blocks IL-13 signaling to reduce inflammatory responses and improve skin barrier function.
$0.032BPart D
PeakADBRY is in peak commercial lifecycle with $32M in Part D spending; teams are likely focused on market penetration and retention strategies against growing competitive pressure (30% intensity).
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ADBRY positions professionals at the intersection of peak-stage biologic commercialization and competitive atopic dermatitis market dynamics. Roles emphasize clinical education, payer negotiations, and differentiation against entrenched competitors.
Brand ManagerMedical Science Liaison
Worked on ADBRY at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.